Cupid invests in GII Healthcare Investment
GII is a leading investment firm with assets under management exceeding US$ 3.5 billion with presence across Saudi Arabia, UAE, Europe, USA and India
GII is a leading investment firm with assets under management exceeding US$ 3.5 billion with presence across Saudi Arabia, UAE, Europe, USA and India
LEQSELVI now available for prescription in U.S. nationwide, offering a new option for eligible patients
Baxdrostat demonstrated a statistically significant and clinically meaningful reduction of systolic blood pressure compared with placebo
This collaboration marks a significant milestone for Abluva as the company aims to deliver value and innovative solutions in agentic AI security
IGI partners with AbbVie and grants exclusive rights to globally develop, manufacture, and commercialize ISB 2001 across North America, Europe, Japan, and Greater China
It is intended for contrast enhancement in MRI scans
Apollo AyurVAID’s product line features clinically proven formulations certified safe by NABL-accredited laboratories for heavy metals, aflatoxins, microbial content
Xtandi is approved in over 80 countries, including the U.S., EU, and Japan
Acquisition aligns with Merck’s science-led business development strategy and expands pipeline and portfolio of treatments for cardio-pulmonary diseases
Subscribe To Our Newsletter & Stay Updated